CD47-SIRPα signaling-inspired engineered monocytes for preventing the progression of atherosclerotic plaques.

ABSTRACT: The accumulation of foam cells in the subendothelial space of the vascular wall to form plaques is the real cause of atherosclerotic lesions. Conventional interventions, such as statins and anti-cytokine or anti-inflammatory therapies, suffer problems in terms of their short therapeutic outcomes and potential disruption of the immune system. The development of more efficient therapeutics to restrict the initial progression of plaques appears to be crucial for treating and preventing atherosclerosis. Decreasing foam cell formation by reversing the excessive phagocytosis of modified low-density lipoprotein (LDL) in macrophages is highly desirable. Here, we developed a strategy based on engineered monocytes to dynamically regulate lipid uptake by macrophages inspired by a CD47-SIRPα signaling

SUBMITTER: Xia Q 

PROVIDER: S-EPMC11357865 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature